Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13338 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Norio Ohmagari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd., Ministry of Health, Labour and Welfare, EPS Corporation.
Abstract (Originalsprache)
Background
This phase 2b/3, randomized, placebo‐controlled trial explored the efficacy and evaluated the safety of ensitrelvir. This trial involved individuals with asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and patients with mild symptoms of coronavirus disease 2019 (COVID‐19).
Methods
The trial was conducted at 57 medical institutions in Japan, South Korea, and Vietnam (study period: January 6–August 14, 2022). Eligible participants were randomized (1:1:1) to the ensitrelvir 125‐mg, ensitrelvir 250‐mg, or placebo group, received the allocated intervention orally, and were followed up until Day 28. Participants self‐rated the severity of 14 typical COVID‐19 symptoms and recorded the data in an electronic diary.
Results
In total, 572 participants (194, 189, and 189 in the ensitrelvir 125‐mg, ensitrelvir 250‐mg, and placebo groups, respectively) were included in the intention‐to‐treat population. Ensitrelvir 125‐mg group observed a 77% reduction in the risk of developing any of the 14 COVID‐19 symptoms or fever and a 29% reduction in the risk of worsening of such symptoms or fever versus placebo (statistically nonsignificant). The viral RNA, viral titer, and time to infectious viral clearance observed a statistically significant decrease versus placebo. Most treatment‐related adverse events (TEAEs) were mild to moderate in severity, and the most common TEAE observed across groups was a decrease in high‐density lipoprotein.
Conclusions
Our exploratory results suggest a potential reduction in the risk of development or worsening of COVID‐19 symptoms with ensitrelvir. Ensitrelvir showed antiviral efficacy and was well tolerated. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT2031210350.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
- The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan.
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of General Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan.
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd, Osaka, Japan.
ORCID-Profile: Takeki Uehara
Förderung
- Shionogi & Co., Ltd.
- Ministry of Health, Labour and Welfare
- EPS Corporation
- Shionogi
Zitieren
APA
Ohmagari, N., Yotsuyanagi, H., Doi, Y., Yamato, M., Imamura, T., Sakaguchi, H., Yamanaka, H., Imaoka, R., Fukushi, A., Ichihashi, G., Sanaki, T., Tsuge, Y., Uehara, T., & Mukae, H. (2024). Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13338
Vancouver
Ohmagari N, Yotsuyanagi H, Doi Y, Yamato M, Imamura T, Sakaguchi H, et al. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13338
BibTeX
@article{Ohmagari2024,
author = {Ohmagari, Norio and Yotsuyanagi, Hiroshi and Doi, Yohei and Yamato, Masaya and Imamura, Takumi and Sakaguchi, Hiroki and Yamanaka, Hideki and Imaoka, Ryosuke and Fukushi, Akimasa and Ichihashi, Genki and Sanaki, Takao and Tsuge, Yuko and Uehara, Takeki and Mukae, Hiroshi},
title = {Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13338}
}
EUVIMED